Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape

Abstract

A Corrigendum on Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape by Xie S, Li S, Tian J and Li F (2020). Front. Pharmacol. 11:73. doi: 10.3389/fphar.2020.00073 In the original article, there was a mistake in Table 2 as published. The row headers of Table 2 in the article are missing. The corrected Table 2 appears below. Table 2 Characteristics of the clinical trials of iguratimod in combination for RA. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. Duan, X. W., Zhang, X. L., Mao, S. Y., Shang, J. J., Shi, X. D. (2015). Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin. Rheumatol. 34 (9), 1513–1519. doi: 10.1007/s10067-015-2999-6 PubMed Abstract | CrossRef Full Text | Google Scholar Ebina, K., Miyama, A., Tsuboi, H., Kaneshiro, S., Nishikawa, M., Owaki, H., et al. (2019). The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod. Rheumatol. 29 (4), 581–588. doi: 10.1080/14397595.2018.1486939 PubMed Abstract | CrossRef Full Text | Google Scholar Hara, M., Ishiguro, N., Katayama, K., Kondo, M., Sumida, T., Mimori, T., et al. (2014). Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol. 24 (3), 410–418. doi: 10.3109/14397595.2013.843756 PubMed Abstract | CrossRef Full Text | Google Scholar Ishiguro, N., Yamamoto, K., Katayama, K., Kondo, M., Sumida, T., Mimori, T., et al. (2013). Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod. Rheumatol. 23 (3), 430–439. doi: 10.1007/s10165-012-0724-8 PubMed Abstract | CrossRef Full Text | Google Scholar Suto, T., Yonemoto, Y., Okamura, K., Sakane, H., Takeuchi, K., Tamura, Y., et al. (2019). The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis. Mod. Rheumatol. 29 (5), 775–781. doi: 10.1080/14397595.2018.1510879 PubMed Abstract | CrossRef Full Text | Google Scholar Xia, Z., Lyu, J., Hou, N., Song, L., Li, X., Liu, H. (2016). Iguratimod in combination with methotrexate in active rheumatoid arthritis: Therapeutic effects. Z. Rheumatol. 75 (8), 882–833. doi: 10.1007/s00393-015-1641-y CrossRef Full Text | Google Scholar Yoshikawa, A., Yoshida, S., Kimura, Y., Tokai, N., Fujiki, Y., Kotani, T., et al. (2018). Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study. Mod. Rheumatol. 28 (2), 227–234. doi: 10.1080/14397595.2017.1336865 PubMed Abstract | CrossRef Full Text | Google Scholar Zheng, N., Guo, C., Wu, R. (2018). Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate– cyclosporin A–hydroxychloroquine–prednisone. Scandinavian. J. Rheumatol. 47 (5), 422–424. doi: 10.1080/03009742.2017.1376109 CrossRef Full Text | Google Scholar Keywords: iguratimod, rheumatoid arthritis, NF-kappa B, randomized controlled trial, pharmacology Citation: Xie S, Li S, Tian J and Li F (2020) Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Front. Pharmacol. 11:488. doi: 10.3389/fphar.2020.00488 Received: 23 March 2020; Accepted: 27 March 2020; Published: 08 April 2020. Edited and reviewed by: Gerard Bannenberg, GOED, United States Copyright © 2020 Xie, Li, Tian and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Fen Li, Lifen0731@csu.edu.cn